A contrast medium (or contrast agent) is a chemical substance applied to the anatomical or functional region being imaged, to increase the differences between different tissues or between normal and abnormal tissue.
The chemical composition of the contrast media determines the specific usage. The intention in the development of ultrasound contrast media is a high contrast between blood and tissues in different organs or even tumors.

See also ultrasound contrast agents, the info sheet gives an overview and more in-depth information about different types of ultrasound contrast medium.

Ultrasound waves are reflected when there is a change in acoustic impedance. The larger the change, the more ultrasound is reflected. Microbubbles have an enormous difference in acoustic impedance as compared to surrounding fluid due to the large differences in density, elasticity and compressibility.
At low acoustic power (mechanical index less than 0.1), the mechanism of ultrasound reflection is that of Rayleigh scattering and the microbubbles may be regarded as point scatterers. The scattering strength of a point scatterer is proportional to the sixth power of the particle radius and to the fourth power of the ultrasound frequency;; the echogenicity of such contrast agent is therefore highly dependent upon particle size and transmit frequency. The backscattered intensity of a group of point scatterers is furthermore directly proportional to the total number of scatterers in the insonified volume. The concentration of the contrast medium is of importance.

See also Backscatter Energy, Cross-section Scattering.

Bubble specific imaging methods rely usually on non-linear imaging modes. These contrast imaging techniques are designed to suppress the echo from tissue in relation to that from a microbubble contrast agent.
Stimulated acoustic emission (SAE) and phase / pulse inversion imaging mode (PIM) are bubble specific modes, which can image the tissue specific phase.
In SAE mode bubble rupture is seen as a transient bright signal in B-mode and as a characteristic mosaic-like effect in velocity 2D color Doppler.
PIM are Doppler modes and detect non-linear echoes from microbubbles. In pulse inversion imaging modes the transducer bandwidth extends, resulting in improved spatial resolution and more contrast.

See also Contrast Pulse Sequencing, Microbubble Scanner Modification, Narrow Bandwidth, Contrast Medium, Dead Zone.

From Bayer Schering Pharma AG:
Echovist-200® was an effectively one-pass-only contrast medium for contrast sonography and Doppler-echocardiographic examinations for the detection, exclusion or follow-up of pathological states leading to hemodynamic changes. Because of the short intravascular life of the microparticles and microbubbles, transit through the pulmonary circulation is unusual. In cardiac evaluations Echovist-200® has been replaced by newer ultrasound contrast agents (USCA), therefore the manufacturing was discontinued.
Another range of echo contrast application is the female genital tract, in particular for the demonstration or exclusion of acquired or congenital changes of the uterine cavity and for the visualization of the Fallopian tubes and investigation of their patency.
1 g Echovist-200 granules contain 1 g D-galactose microparticles. 1 ml aqueous solution for production of the suspension contains 200 mg D-galactose.
Brand names in other countries: Ecovist.

From Bayer Schering Pharma AG:
Available in Europe since 1996 and in Japan since 1999. Currently, the marketing situation is unclear.
Levovist® is a first generation USCA consisting of galactose (milk sugar) ground into tiny crystals whose irregular surfaces act as nidation sites on which air pockets form when it is suspended in water, much as soda water bubbles form at small irregularities on the surface of the glass. A trace of palmitic acid is added as a surfactant to stabilize the resultant microbubbles. When Levovist® dissolves in blood, air trapped inside the galactose is released as free gas bubbles. These bubbles have a weak encapsulating shell and are easily destroyed by ultrasound.
Different contrast ultrasonography methods have been developed since the introduction of Levovist®. Initially, Levovist® was an echo contrast medium for improving sensitivity in color Doppler and Power Doppler examinations, but was found to suffer from significant blooming, making it difficult to observe small blood vessels. However, Levovist® improves the accuracy of echocardiographic examinations in such indications as assessment of left ventricular function.
In addition to their vascular phase, some ultrasound contrast agents (USCAs) can exhibit a tissue- or organ-specific phase. Levovist® can accumulate within the liver and the spleen for up to 20 min once it has disappeared from the blood pool and improves the detectability of focal liver lesions and allows more reliable control of interventional tumor treatments. Varied types of information can be obtained by applying contrast imaging at different times after the injection using Levovist® in both the arterial phase and the late organ-specific phase.
1 g Levovist® granules contain 999 mg D-galactose and 1 mg palmitic acid.
Brand names in other countries: Levovist/Levograf